Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)

非洲抗逆转录病毒治疗时代的卡波西肉瘤计划 (KEAAP)

• 批准号: 10598769
• 负责人: Julius David Mwaiselage
• 金额: $ 92.06万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10598769
• 关键词: AIDS related cancer; Address; Africa; Africa South of the Sahara; Bilateral; Cancer Biology; Cancer Center; Cancer Patient; Cancer Research Infrastructure; Caring; Chronic; Collaborations; Core Facility; Country; Detection; Diagnosis; Disease; Educational workshop; Ensure; Epidemic; Etiology; Fostering; Funding; Future; Goals; HIV; HIV-1; HIV/AIDS; Health Sciences; Hospitals; Human Herpesvirus 8; Human Resources; Immune response; Immunosuppression; Incidence; Individual; Kaposi Sarcoma; Lateral; Lead; Leadership; Learning; Link; Louisiana; Malignant Neoplasms; Mediating; Mentors; Molecular; Oceans; Oncology; Outcome; Pathogenesis; Pathology; Patients; Persons; Pilot Projects; Population; Positioning Attribute; Public Health; Research; Research Infrastructure; Research Personnel; Research Project Grants; Residual state; Staging; Tanzania; Teaching Hospitals; Technology Transfer; Tissues; Training; Training Activity; Training Programs; Training and Infrastructure; United States; Universities; Viral; Vision; Zambia; anticancer research; antiretroviral therapy; clinical care; health disparity populations; immune activation; low and middle-income countries; metabolome; next generation; prevent; programs; success

There are currently over 1.2 million people in Zambia and 1.7 million in Tanzania who are living with HIV/AIDS. Concomitant to the HIV epidemic, there is a high incidence of HIV/AIDS-associated malignancies (HIVAM) in these two countries. Even in this era of antiretroviral therapy (ART) Kaposi sarcoma (KS) has remained one of the most common HIVAM. This underscores a critical need for research in the context of ART-mediated changes in the HIV epidemic so that we are better equipped to diagnose, manage, and prevent KS in sub- Saharan Africa (SSA). To address this need, the overall vision of the “Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)” is to build a collaborative network between the Cancer Diseases Hospital (CDH) and University Teaching Hospitals (UTH) in Zambia, the Ocean Road Cancer Institute (ORCI) in Tanzania, and the Stanley S Scott Cancer Center at the Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO) to conduct cutting edge research that will lead to a better understanding of KS, and in parallel, continue to enhance HIVAM and non-HIVAM research capacity in Zambia and Tanzania to meet the needs of the cancer patients. KEAAP’s theme centers on the research gaps of the KS disease spectrum, from detection, to care and outcomes, to deciphering KS pathogenesis and immune response towards achieving KEAAP’s overall goal to prevent and curing the disease. KEAAP’s immediate objective is to further enhance the cancer research infrastructure in CDH/UTH and ORCI through support for interdisciplinary and bilateral KS research projects to address some of the research gaps in SSA: 1) KS diagnosis and disease staging, and linking to care; 2) changes in the immune response and metabolomes in KS patients upon treatment; and 3) identification and characterization of KSHV tissue reservoirs, and the effects of ART and HIV on these reservoirs. This proposed consortium will provide diverse training activities in the U.S., Zambia, and Tanzania to engage the next generation of low and middle income countries (LMICs) and U.S. cancer researchers, increase local expertise, and enhance the transfer of technology. KEAAP’s goal will be accomplished through the completion of three specific aims:1) Develop the cancer research infrastructure at UTH/CDH and ORCI through the establishment and enhancement of three core facilities; 2) Provide an opportunity for former Fogarty trained fellows to lead three hypothesis-driven KS research projects; 3) Develop a pipeline of next- generation U.S. and LMICs cancer researchers through a) in-country workshops, b) pilot project funding, and c) short-term U.S. and in-country training. KEAAP is high impact because it builds on successful ongoing Fogarty and NCI training programs; it will implement a cross-disciplinary and tri-lateral research and training program that are driven by our Tanzanian and Zambian collaborators with broad local support to ensure their sustainability. The lessons learned will also benefit Louisiana HIV-1 and cancer research since the state has the fifth largest population of people living with HIV, mostly among its health disparities population.

目前，赞比亚有120多万人感染艾滋病毒/艾滋病，坦桑尼亚有170万人感染艾滋病毒/艾滋病。 伴随着艾滋病毒的流行，艾滋病毒/艾滋病相关恶性肿瘤（HIVAM）的发病率很高， 这两个国家即使在这个抗逆转录病毒治疗（ART）的时代，卡波西肉瘤（KS）仍然是 最常见的HIVAM。这强调了在ART介导的背景下进行研究的迫切需要。 艾滋病毒流行的变化，使我们能够更好地诊断，管理和预防亚- 撒哈拉非洲。为了满足这一需求，“卡波西肉瘤在ART时代， 非洲计划（KEAAP）”是建立一个合作网络之间的癌症疾病医院（CDH）和 赞比亚的大学教学医院（UTH）、坦桑尼亚的海洋之路癌症研究所（ORCI）和 新奥尔良路易斯安那州立大学健康科学中心斯坦利·S·斯科特癌症中心 （LSUHSC-NO）进行尖端研究，这将导致更好地了解KS，同时， 继续加强赞比亚和坦桑尼亚的艾滋病毒/艾滋病和疟疾研究能力，以满足 癌症患者。KEAAP的主题集中在KS疾病谱的研究空白，从 检测，护理和结果，破译KS发病机制和免疫反应，以实现 KEAAP的总体目标是预防和治疗疾病。KEAAP的近期目标是进一步加强 CDH/UTH和ORCI的癌症研究基础设施，通过支持跨学科和双边KS 研究项目，以解决SSA的一些研究空白：1）KS诊断和疾病分期， 与护理相关; 2）KS患者治疗后免疫应答和代谢组的变化;以及3） KSHV组织储库的鉴定和表征，以及ART和HIV对这些储库的影响。 水库这个拟议中的联盟将在美国提供各种培训活动，赞比亚和坦桑尼亚 吸引下一代中低收入国家和美国癌症研究人员， 增加当地专门知识，加强技术转让。KEAAP的目标将通过 完成三个具体目标：1）发展UTH/CDH和ORCI的癌症研究基础设施 通过建立和加强三个核心设施; 2）为前 福格蒂培训研究员领导三个假设驱动的KS研究项目; 3）开发下一个管道- 通过a）国内研讨会，B）试点项目资助，以及 3.短期美国和国内培训。KEAAP具有很高的影响力，因为它建立在成功的持续 Fogarty和NCI培训计划;它将实施跨学科和三边研究和培训 该计划由我们的坦桑尼亚和赞比亚合作者在当地广泛支持下推动， 持续发展吸取的教训也将有利于路易斯安那州的艾滋病毒-1和癌症研究，因为该州已经 艾滋病毒感染者人数居第五位，其中大多数是健康状况不佳的人口。